Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas

Journal of Clinical Oncology

Volumn 19, Issue 8, 2001, Pages 2189-2200

  Andrews, D W ^a   Resnicoff, M ^a   Flanders, A E ^a   Kenyon, L ^a   Curtis, M ^a   Merli, G ^a   Baserga, R ^a   Iliakis, G ^a   Aiken, R D ^a  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; SOMATOMEDIN C RECEPTOR;

ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GLIOMA CELL; HUMAN; IMMUNE RESPONSE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; TREATMENT OUTCOME; WESTERN BLOTTING;

EID: 0035871490     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.8.2189     Document Type: Article

References (53)

1. Clinical outcome of gliosarcoma compared with glioblastoma multiforme: North Central Cancer Treatment Group results
2. Insulin-like growth factor I receptor primary structure: Comparison with insulin receptor suggests structural determinants that define functional specificity
3. Molecular and cellular aspects of the insulin-like growth factor I receptor
4. The insulin-like growth factor I receptor: A key to tumor growth?
5. The IGF-I receptor and cancer
6. A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer
7. Effect of the insulin-like growth factor I receptor on ionizing radiation-induced cell death in mouse embryo fibroblasts
8. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation
9. A soluble insulin-like growth factor I receptor that induces apoptosis of tumor cells in vivo and inhibits tumorigenesis
10. Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor I receptor mutant
11. Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors
12. Antisense-mediated reduction in insulin-like growth factor-I receptor expression suppresses the malignant phenotype of a human alveolar rhabdomyosarcoma
13. Growth inhibition of MCF-7 breast cancer cells by stable expression of an insulin-like growth factor I receptor antisense ribonucleic acid
14. Antitumor effects of an adenovirus expressing antisense insulin-like growth factor I receptor on human lung cancer cell lines
15. Loss of the metastatic phenotype in murine carcinoma cells expressing an antisense RNA to the insulin-like growth factor receptor
16. Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo
17. Inhibition of tumor growth by a dominant negative mutant of the insulin-like growth factor I receptor with a bystander effect
18. The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo
19. The role of the IGF-I receptor in apoptosis
20. Inhibition of insulin-like growth factor I receptor expression in neuroblastoma cells induces the regression of established tumors in mice
21. The role of the insulin-like growth factor I receptor in transformation and apoptosis
22. Correlation between apoptosis, tumorigenesis, and levels of insulin-like growth factor I receptors
23. Regression of C6 rat brain tumors by cells expressing an antisense insulin-like growth factor I receptor RNA
24. Integration of functional brain mapping in image-guided neurosurgery
25. Inhibition of rat C6 glioblastoma tumor growth by expression of insulin-like growth factor I receptor antisense mRNA
26. Glial fibrillary acidic (GFA) protein immunocytochemistry in development and neuropathology
27. Response criteria for phase II studies of supratentorial malignant glioma
28. Imaging of adult central nervous system primary malignant gliomas. Staging and follow-up
29. The clinical evaluation of chemotherapeutic agents in cancer
30. MRI measurement of brain tumor response: Comparison of visual metric and automatic segmentation
31. Stereotactic histologic correlations of computed tomography- and magnetic resonance imaging-defined abnormalities in patients with glial neoplasms
32. Positron emission tomography with 11C-methionine and computed tomography of intracranial tumours compared with histopathologic examination of multiple biopsies
33. Cerebral astrocytomas: Histopathologic correlation of MR and CT contrast enhancement with stereotactic biopsy
34. Antitumor effects elicited by antisense-mediated downregulation of the insulin-like growth factor I receptor
35. Effect of a major histocompatibility complex class I peptide on insulin-like growth factor-I receptor internalization and biological signaling
36. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs
37. A novel class of peptides that induce apoptosis and abrogate tumorigenesis in vivo
38. Antisense insulin-like growth factor I transferred into a rat hepatoma cell line inhibits tumorigenesis by modulating major histocompatibility complex I cell surface expression
39. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1
40. Radiation therapy for neoplasms of the brain
41. Bromodeoxyuridine labeling index in glioblastoma multiforme: Relation to radiation response, age, and survival
42. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas: The Polymer-Brain Tumor Treatment Group
43. A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma
44. Steroid-induced CT changes in patients with recurrent malignant glioma
45. Immunohistological and functional analyses of lymphoid infiltrates in human glioblastomas
46. Relationship of lymphocyte invasion and survival of brain tumor patients
47. Lymphocyte-mediated cytotoxicity against gliomas
48. Lymphocytic infiltration in gliomas: Evidence of possible host resistance
49. Prognostic value of round cell (lymphocyte) infiltration in malignant gliomas
50. Lymphocytic infiltrates in primary glioblastomas and recidivous gliomas. Incidence, fate, and relevance to prognosis in 228 operated cases
51. Local neurochemicals and site-specific immune regulation in the CNS
52. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature